tiprankstipranks
Trending News
More News >

Baker Bros. Advisors Lp Insider Profile

179 Followers
Baker Bros. Advisors Lp, Ten Percent Owner at BioCryst, holds 7.96M shares in Kymera Therapeutics (Ticker: KYMR), holds 4.69M shares in Entrada Therapeutics Inc (Ticker: TRDA), holds 425.01K shares in KALA BIO (Ticker: KALA). Most recently, Baker Bros. Advisors Lp Bought ― shares of Kymera Therapeutics on Dec 11, 2025 for an estimated value of $172.50M.
tipranks
Baker Bros. Advisors Lp

Baker Bros. Advisors Lp
BioCryst (BCRX)
Ten Percent Owner

Ranked #250 out of 105,077 Corporate Insiders

Profitable Transactions

56%
55 out of 98 Profitable Transactions

Average Return

+28.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$11B
26.83%
25.79%
10.38%
9.84%
27.17% Others
A breakdown of Baker Bros. Advisors Lp's holdings

Insider Roles

BeOne Medicines
(ONC)
Director
Incyte
(INCY)
Director, Ten Percent Owner
Madrigal Pharmaceuticals
(MDGL)
Director
ACADIA Pharmaceuticals
(ACAD)
Director, Ten Percent Owner
+21 other positions
Roles that Baker Bros. Advisors Lp holds in companies

Most Profitable Insider Trade

Stock:
Invitae
(NVTAQ)
Rating:Informative Buy
Date:Mar 29, 2018 - Mar 29, 2019
Return:+399.30%
The most profitable trade made by Baker Bros. Advisors Lp

Baker Bros. Advisors Lp's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
BioCryst
Aug 16, 2016
Ten Percent Owner
Informative Sell
20.25M
$114.18M
BLCM
Bellicum Pharmaceuticals
Nov 24, 2023
Uninformative Buy
$160.49K
BeOne Medicines
May 22, 2025
Director
Uninformative Buy
$2.88B
ACGN
Aceragen
Jul 03, 2019
Uninformative Buy
15.47K
$1.65M
ALXN
Alexion Pharmaceuticals
May 18, 2020
Uninformative Buy
$1.47B
Kiniksa Pharmaceuticals
Jun 05, 2025
Director
Uninformative Buy
$113.54M
Hookipa Pharma
Apr 23, 2019
Former 10% owner
Informative Buy
12.50M
$722.24K
Kodiak Sciences
Jun 06, 2022
Director, Ten Percent Owner
Informative Buy
4.45M
$385.30M
IGMS
IGM Biosciences
Aug 18, 2025
Uninformative Sell
$0.00
BCEL
Atreca
Oct 23, 2023
Informative Sell
109.90K
$267.40K
Zymeworks
Director
Prelude Therapeutics
Jan 29, 2021
Director, Ten Percent Owner
Uninformative Buy
133.33K
$15.08M
Spyre Therapeutics
Director
Talis Biomedical
Nov 19, 2021
Director, Ten Percent Owner
Informative Buy
218.00K
$12.20M
TScan Therapeutics
May 12, 2022
Director
Informative Buy
2.56M
$2.71M
Entrada Therapeutics Inc
Nov 24, 2025
Ten Percent Owner
Informative Buy
261.68K
$50.71M
DBV Technologies SA - American
Jun 13, 2022
Director, Ten Percent Owner
Uninformative Buy
$567.02M
Madrigal Pharmaceuticals
Aug 20, 2025
Director
Informative Buy
24.98M
$1.11B
vTv Therapeutics
Sep 05, 2025
Director
Uninformative Buy
$4.64M
Kymera Therapeutics
Dec 11, 2025
Director, Ten Percent Owner
Informative Buy
172.50M
$698.61M
Bicycle Therapeutics
Jan 06, 2025
Director, Ten Percent Owner
Uninformative Buy
$74.30M
Immunocore Holdings
Mar 19, 2025
Director
Informative Buy
23.99M
$76.76M
KALA BIO
Oct 02, 2025
Former 10% owner
Informative Sell
1.05M
$294.95K
Replimune Group
Director, Ten Percent Owner
Denali Therapeutics
Jun 05, 2025
Director
Uninformative Buy
$59.34M
Celcuity
Sep 10, 2025
Ten Percent Owner
Informative Buy
9.57M
$726.70M
MRTX
Mirati Therapeutics
Nov 13, 2017
Informative Buy
2.20M
$2.13M
Neurogene
Oct 10, 2023
Director, Former 10% Owner
Uninformative Buy
$9.65M
NVTAQ
Invitae
Mar 29, 2018
Informative Buy
5.00M
$83.09K
ACADIA Pharmaceuticals
Jun 02, 2025
Director, Ten Percent Owner
Uninformative Buy
$1.06B
Xoma
Jul 23, 2015
Former 10% owner
Informative Sell
11.99M
$2.40M
GHDX
Genomic Health
Oct 03, 2019
Uninformative Buy
124.47K
$484.81M
Incyte
Oct 02, 2025
Director, Ten Percent Owner
Uninformative Buy
$2.77B
SGEN
Seagen
Jun 02, 2023
Uninformative Buy
$9.84B
GEVA
Synageva
List of latest transactions for each holding click on a transaction to see Baker Bros. Advisors Lp's performance on stock

Baker Bros. Advisors Lp insider profile FAQ

What is the percentage of profitable transactions made by Baker Bros. Advisors Lp?
The percentage of profitable transactions made by Baker Bros. Advisors Lp is 56%.
    What is the average return per transaction made by Baker Bros. Advisors Lp?
    The average return per transaction made by Baker Bros. Advisors Lp is 28.20%.
      What stocks does Baker Bros. Advisors Lp hold?
      Baker Bros. Advisors Lp holds: BCRX, BLCM, ONC, ACGN, ALXN, KNSA, HOOK, KOD, IGMS, BCEL, ZYME, PRLD, SYRE, TLIS, TCRX, TRDA, DBVT, MDGL, VTVT, KYMR, BCYC, IMCR, KALA, REPL, DNLI, CELC, MRTX, NGNE, NVTAQ, ACAD, XOMA, GHDX, INCY, SGEN, GEVA stocks.
        What was Baker Bros. Advisors Lp’s latest transaction?
        Baker Bros. Advisors Lp latest transaction was an Informative Buy of $172.50M.
          What was Baker Bros. Advisors Lp's most profitable transaction?
          Baker Bros. Advisors Lp’s most profitable transaction was an Informative Buy of NVTAQ stock on March 29, 2018. The return on the trade was 399.30%.
            What is Baker Bros. Advisors Lp's role in BioCryst?
            Baker Bros. Advisors Lp's role in BioCryst is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.